Raised calcium in an adult with cancer
Corrected Ca above the lab range (about 2.6 mmol/L) or ionised Ca above the lab range. Adults only. Pregnancy: get specialist advice; do not use this pathway.
All Pathways
Hematology & OncologyEmergency
Hypercalcemia of Malignancy Management
Hypercalcemia of Malignancy Management: Raised calcium in an adult with cancer → Confirm and assess (do not delay treatment) → Find the cause and stop d...
Pathway Overview
21 steps
Algorithm Steps
21 total
01Start 02Action Confirm and assess (do not delay treatment)
Repeat calcium, check ECG, kidneys and volume status.
- Corrected Ca (mmol/L) = measured Ca + 0.02 x (40 - albumin g/L); use ionised Ca if albumin is very abnormal
- ECG: short QT, bradycardia, AV block, arrhythmia
- Creatinine, eGFR, urea, K, Mg, phosphate
- Symptoms: confusion, drowsiness, polyuria, thirst, nausea, vomiting, constipation
- Advanced cancer: discuss goals of care early; hypercalcaemia may be a terminal event
03Action Find the cause and stop drugs that raise calcium
Send tests now; start treatment before results return.
- Send PTH, PTHrP, 1,25-dihydroxyvitamin D and 25-OH vitamin D
- Stop thiazides, lithium, calcium and vitamin D supplements
- PTH high or normal: primary hyperparathyroidism or parathyroid carcinoma; get endocrine advice
- Digoxin: hypercalcaemia increases toxicity; ECG monitoring and digoxin level
04Decision Severity by corrected calcium
Mild: below 3.0 mmol/L. Moderate: 3.0-3.5 mmol/L. Severe: above 3.5 mmol/L. Treat as moderate or severe if symptoms, ECG changes or AKI at any level.
- Mild, no symptoms
05Action Mild (below 3.0 mmol/L) and no symptoms
Often managed as an outpatient.
- Oral fluids; stop drugs that raise calcium
- Treat the cancer
- Symptoms or calcium rising: treat as moderate (admit, IV fluids, IV bisphosphonate)
- Recheck calcium and creatinine; give clear return advice
06Outcome Hypercalcaemia controlled
Continue cancer treatment; recheck calcium at each review.
- Moderate or severe
07Action Moderate or severe (3.0 mmol/L or more) or symptoms: admit
Needs IV fluids and an antiresorptive drug.
- Severe (above 3.5 mmol/L), confusion, arrhythmia or ECG changes: urgent treatment and cardiac monitoring
- Seek oncology and endocrinology advice
08Warning Heart failure, oliguric AKI or dialysis: fluids can cause overload
Give fluids in small volumes with frequent review. Do not withhold the antiresorptive.
- Severe hypercalcaemia with renal failure or fluid overload: urgent renal referral for haemodialysis (low-calcium dialysate)
- Loop diuretic only for fluid overload after volume repletion; it is not a calcium-lowering treatment
- Elderly: reassess volume often
09Action IV 0.9% sodium chloride (first step for moderate or severe)
Restore volume while the antiresorptive takes effect.
- 0.9% sodium chloride 4-6 L over 24 h if heart and kidneys allow (adult)
- Reassess volume, urine output and chest every few hours
- No routine loop diuretic
- Hydrate before and during IV bisphosphonate
10Warning Before calcium-lowering drugs: check kidneys, vitamin D, pregnancy
These change the drug choice.
- CrCl below 30 mL/min or dialysis: zoledronic acid not recommended; denosumab carries a high risk of severe hypocalcaemia. Life-threatening: pamidronate (slow infusion) or haemodialysis, with specialist advice
- Low 25-OH vitamin D: higher risk of hypocalcaemia after treatment
- Pregnancy: bisphosphonates, denosumab and calcitonin are contraindicated; get specialist advice
11Decision Severe: above 3.5 mmol/L or severe symptoms?
Severe symptoms: confusion, drowsiness, arrhythmia, ECG changes.
- If Yes
12Action Severe: add calcitonin as a bridge (48-72 h)
Give with an IV bisphosphonate or denosumab, never instead of one.
- Adult: calcitonin salmon 4 IU/kg SC or IM every 12 h (AU PI range 5-10 IU/kg/day)
- Acts in hours; effect is modest
- Stop after 48-72 h: tachyphylaxis
- Do not give if allergic to salmon calcitonin. Supply in Australia has been short: check local stock
13Decision High 1,25-dihydroxyvitamin D (lymphoma or granulomatous disease)?
Calcitriol-mediated hypercalcaemia responds to glucocorticoids.
- If Yes
14Action Calcitriol-mediated: start a glucocorticoid first
Lymphoma or granulomatous disease with high 1,25-dihydroxyvitamin D.
- Adult: prednisolone 40 mg orally daily; calcium usually falls in 2-4 days
- Untreated suspected lymphoma: discuss biopsy with haematology before steroids; do not delay if life-threatening
- Still severe or symptomatic on a glucocorticoid: add IV bisphosphonate or denosumab (next step)
15Decision Choose an antiresorptive: IV bisphosphonate or denosumab
Give one to every patient with moderate or severe HCM. Calcitriol-mediated: add one only if still severe or symptomatic on a glucocorticoid. Australia: IV bisphosphonate first; denosumab is TGA-indicated for HCM refractory to IV bisphosphonate.
- IV bisphosphonate
16Action IV bisphosphonate (CrCl 30 mL/min or more)
Zoledronic acid is first line. Hydrate first. Check creatinine before each dose.
- Adult: zoledronic acid 4 mg IV over at least 15 min; no dose reduction for HCM if CrCl 30 mL/min or more
- OR pamidronate 30-90 mg IV by measured calcium: up to 3.0 mmol/L 30 mg; 3.0-3.5 30-60 mg; 3.5-4.0 60-90 mg; above 4.0 90 mg
- Pamidronate rate: max 60 mg/h; renal impairment max 90 mg over 4 h
- Calcium falls over 2-4 days; zoledronic acid can be repeated after at least 7 days
17Action Monitor response and harms
Calcium should start to fall within 48-72 h.
- Calcium, creatinine, K, Mg, phosphate at least daily; more often if severe
- Fluid balance and daily weight
- Watch for hypocalcaemia after bisphosphonate or denosumab. Symptomatic: adult calcium gluconate 10% 10-20 mL IV over 10 min with ECG monitoring; check and correct Mg
- Continue IV fluids until euvolaemic and drinking
18Decision Calcium falling at 48-72 h?
Yes: plan maintenance. No or recurs: see next step. A bisphosphonate lowers calcium over 2-4 days; call it refractory only if calcium is still high 7 days or more after it.
- If Yes
19Action Calcium controlled: prevent recurrence
Relapse is common without cancer treatment (median 30 days after one zoledronic acid dose).
- Treat the underlying cancer
- Ongoing zoledronic acid or denosumab only if oncology indicates
- Withhold calcium and vitamin D while hypercalcaemic; on denosumab start them once calcium is normal
- Dental review before ongoing antiresorptives (osteonecrosis of the jaw)
- Do not stop denosumab without a plan: rebound hypercalcaemia can occur
- Path rejoins step 06Shared downstream outcome
If No20Action Not falling or recurs: reassess, then treat refractory HCM
Get oncology and endocrinology advice. Refractory: calcium still high 7 days or more after an IV bisphosphonate, or recurs.
- Less than 7 days after IV bisphosphonate: continue IV fluids; calcitonin if severe; pamidronate can be repeated if calcium has not fallen after 2 days
- Refractory after IV bisphosphonate: denosumab 120 mg SC, or repeat zoledronic acid 4 mg (at least 7 days after the first dose)
- After denosumab: specialist advice (add or switch to IV bisphosphonate)
- Recheck the cause: calcitriol-mediated: glucocorticoid; parathyroid carcinoma: cinacalcet or an antiresorptive
- Life-threatening with renal failure or fluid overload: haemodialysis (low-calcium dialysate)
- Treat the cancer; review goals of care
- Path rejoins step 06Shared downstream outcome
- Denosumab
21Action Denosumab 120 mg SC (after IV bisphosphonate fails, or specialist choice)
Risk of severe, sometimes fatal hypocalcaemia, highest with CrCl below 30 mL/min, dialysis or low vitamin D.
- Adult: denosumab 120 mg SC, repeat on days 8 and 15, then every 4 weeks
- No renal dose adjustment in the PI, but in CrCl below 30 mL/min or dialysis give only with specialist advice and close calcium checks
- Check calcium before the dose and within 2 weeks after it
- Contraindicated: pregnancy, unhealed dental or oral surgery
- Path rejoins step 17Shared downstream outcome
If No- Path rejoins step 15Shared downstream outcome
If No- Path rejoins step 13Shared downstream outcome
Guideline Source
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline (2023)
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Australia: denosumab is TGA-indicated for HCM only after IV bisphosphonate fails; zoledronic acid is not recommended if CrCl is below 30 mL/min
- Adults only; not for pregnancy. Mechanism tests (PTH, PTHrP, 1,25-dihydroxyvitamin D) guide therapy but must not delay it
- Corrected calcium can mislead in severe hypoalbuminaemia; use ionised calcium
- Does not cover treatment of the underlying cancer or primary hyperparathyroidism
Contraindicated Populations
pregnancychildren
Applicable Regions
AUUSEU
AU: Calcium in mmol/L. Denosumab 120 mg (Xgeva) is TGA-indicated for HCM refractory to IV bisphosphonate; check PBS eligibility. Calcitonin salmon injection supply has been short (s19A imports in 2025); check local stock. Cinacalcet is TGA-indicated for hypercalcaemia in parathyroid carcinoma.
EU: ESE co-sponsored the Endocrine Society guideline.
US: Endocrine Society guideline (co-sponsored by ASBMR and ESE) suggests denosumab over IV bisphosphonate (conditional, low certainty).
Version 2Next review: 2027-09-30
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Absolute Neutrophil Count (ANC)
Absolute neutrophil count from CBC for neutropenia grading
Open page
Compare
AttendMe.ai vs OpenEvidence
See how this pathway workflow compares against OpenEvidence.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Hypercalcemia of Malignancy Management?
The Hypercalcemia of Malignancy Management is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline (2023).
What guideline is the Hypercalcemia of Malignancy Management based on?
This algorithm is based on Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline (2023) (DOI: 10.1210/clinem/dgac621).
What are the limitations of the Hypercalcemia of Malignancy Management?
Known limitations include: Australia: denosumab is TGA-indicated for HCM only after IV bisphosphonate fails; zoledronic acid is not recommended if CrCl is below 30 mL/min; Adults only; not for pregnancy. Mechanism tests (PTH, PTHrP, 1,25-dihydroxyvitamin D) guide therapy but must not delay it; Corrected calcium can mislead in severe hypoalbuminaemia; use ionised calcium; Does not cover treatment of the underlying cancer or primary hyperparathyroidism. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Hypercalcemia of Malignancy Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free